Navigation Links
VAP(R) Cholesterol Test Helps Researchers Identify Treatment Effects of Combination Therapy
Date:11/10/2008

n the VLDL to LDL density range. The combination of ezetimibe/simvastatin + fenofibrate produced greater reductions in VLDL, IDL, and LDL (relative to other treatment groups) and greater improvements in the distribution of LDL subfractions with a shift from smaller, more dense to larger, more buoyant LDL particle size in patients with mixed hyperlipidemia.

Eligible patients for the study were men and women aged 18 to 79 years with mixed hyperlipidemia and no coronary heart disease (CHD), CHD-equivalent disease (except for Type 2 diabetes), or CHD risk score >20% as defined by NCEP ATP III.

VAP technology has been used in more than 100 clinical trials and will continue to play an important role in clinical practice and as a valuable analytical research tool. The VAP Test is available nationwide. For more information on the VAP Test for research and clinical trial applications, call 877.901.8510 or e-mail research@atherotech.com.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on direct measurement of the comprehensive lipid panel using the company's patented VAP(R) Technology. The VAP Test directly measures the cholesterol content of all lipids, components and subclasses. It is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations calling for more accurate, direct low-density lipoprotein (LDL) measurement, which is unaffected by triglycerides. The VAP Cholesterol Test -- the new standard of care for patients at risk for cardiovascular disease -- is available through national and regional diagnostic laboratories and is reimbursed by most payers as well as Medicare. For more information, visit http://www.thevaptest.com.


'/>"/>
SOURCE Atherotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VAP(R) Cholesterol Test Bolsters Biophysical(R) Health Assessment
2. VAP(R) Cholesterol Test From Atherotech Covers an Additional 9 Million of Florida Insured
3. Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008
4. New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
5. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
6. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
7. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
8. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
9. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
10. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
11. New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
(Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... September 1, 2010, ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... Primary Endpoint in Second Phase III Trial in VMA, Confirms... -- LEUVEN, Belgium, September 1, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... that a new market research report is available ... - Pipeline Assessment and Market Forecasts to 2017 ... Women,s Infertility - Pipeline Assessment and Market ... industry analysis specialist, has released its new report, ...
Cached Biology Technology:EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 2EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 3EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 4EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 5EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 6EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 7Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 2Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 3Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 4Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 5Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 6Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 7Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 8Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 9Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 10Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 11Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 6
(Date:7/9/2014)... ranges in which animals can be found, concern mounts ... an increased range for a host mean new territory ... a team of UC Santa Barbara scientists, including parasitologists ... in the Journal of Biogeography , Hechinger, Kuris ... may happen: Hosts may actually lose their parasites when ...
(Date:7/9/2014)... Emerging fungal pathogens pose a greater threat ... population declines of amphibians, bats, corals, bees and ... Florida published in the prestigious journal Nature ... immunological resistance to a deadly chytrid fungus implicated ... resistance is important because it is the basis ...
(Date:7/9/2014)... children with traumatic injuries have identified an immune ... develop a hospital-acquired infection. The study, led by ... in June in the journal Shock , ... lead to the clinical implementation of quick-turnaround immune ... immune system damage following critical illness or injury ...
Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4USF study: Amphibians can acquire resistance to deadly fungus 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... Global Information Inc is pleased to offer attendees their ... the world. Early Bird registration prices end as early ... to 15%. (Photo: http://photos.prnewswire.com/prnh/20120918/CG76491 ) ... | San Francisco, California CHI,s High-Content Analysis ...
... ARLINGTON, Va.Dr. John P. Holdren, White House Office of ... powerful roster of military and government leaders at the ... Conference and ASNE Expo, officials announced Sept. 18. ... S&T and co-chair of the President,s Council of Advisors ...
... is one of the most serious complications related to ... grown in Peru and Chile is a relative of ... The maize is rich in anthocyanins (also known as ... from the Department of Food and Nutrition and Department ...
Cached Biology News:International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 2International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 3International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 4ONR lines up speakers and technologies for 2012 Naval Conference 2Purple corn compound may aid in developing future treatments for Type 2 diabetes, kidney disease 2
... cell with multi-casting chamber is used for handcasting ... format handcast (8.3 x 7.3 cm) or precast ... 3.4-4.4 L of buffer and includes an electrophoresis ... an external refrigerated circulator (not included), lid with ...
...
... This product has been developed to significantly ... labeled proteins. Stability is increased at ... 2-8 centigrade. This product is subjected ... mercury or azide. This formulation insures ...
...
Biology Products: